Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 685Cholangiocarcinoma 113Biliary Tract Neoplasms 95Neoplasms 69Neoplasm Metastasis 66Gallbladder Neoplasms 61Colorectal Neoplasms 49Bile Duct Neoplasms 40Carcinoma, Non-Small-Cell Lung 37Adenocarcinoma 28Carcinoma, Hepatocellular 26Stomach Neoplasms 22Liver Neoplasms 21Colonic Neoplasms 21Ovarian Neoplasms 20Lung Neoplasms 19Breast Neoplasms 18Rectal Neoplasms 15Carcinoma, Pancreatic Ductal 15Pancreatic Adenocarcinoma 13Esophageal Neoplasms 13Sarcoma 12Carcinoma 11Small Cell Lung Carcinoma 10Urinary Bladder Neoplasms 9Gastrointestinal Neoplasms 9Advanced Pancreatic Cancer 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Recurrence 8

Interventions

trifluridine tipiracil drug combination 1romidepsin 1futibatinib 1cabozantinib 1atezolizumab 1Trabectedin 1TAS-116 1Ramucirumab 1Imatinib Mesylate 1HhAntag691 1Gemcitabine 1Fluorouracil 1Dasatinib 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Gemcitabine × Gastrointestinal × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡